Analysis: in 2024, ~66% of 39 public digital health companies lost value, while the Nasdaq rose 32%; in 2021, digital health startups raised a record $29.1B
Post-pandemic demand waned, bringing down former high fliers like Teladoc (-96% from 2021 highs) and Progyny (-60% YTD). … X: Ashley Capoot / @ashleycapoot : New: It's been nearly 5 years since Covid broke out in the U.S., but digital health companies are still reeling. According to a @CNBC analysis of 39 public digital health companies, around 2/3 have lost value this year, while the Nasdaq is up 32%. More! https://www.cnbc.com/... Paul Sonnier / @paul_sonnier : Digital Health Winners & Losers in the Stock Market for 2024 Losers: Progyny, Teladoc Health, GoodRx, Dexcom, 23andMe, Cue Health, Better Therapeutics Winners: Hims & Hers, Doximity, Oscar Health, Waystar (IPO), Tempus AI (IPO) https://www.cnbc.com/... #DigitalHealth LinkedIn: Ashley Capoot : New: If the Covid era marked a boom time for digital health companies, 2024 was the reckoning. According to a CNBC analysis of 39 public digital health companies …
Context & Ripple Effects
Digital health entered the pandemic-era expansion with unusually strong funding: startups raised a record $29.1 billion in 2021, following [[a:965913|a $7 billion first quarter that also raised concerns about overpriced or redundant services]]. The sector's public-market reset now stands out against a sharply rising broader market.
The pattern resembles the earlier retreat among other pandemic-era market winners, but digital health's exposure is more uneven: a large group of public companies declined while some companies, including Waystar, were identified as 2024 winners.
First-order effects
- Public-market investors are repricing digital health companies more harshly than the wider equity market, with Teladoc and Progyny among the named losers.
- The drop in public comparables weakens the market signal for companies whose pandemic-era growth expectations have not translated into sustained investor confidence.
Second-order effects
- Private digital-health startups and prospective public issuers are likely to face tougher valuation benchmarks, especially in categories investors view as overlapping or insufficiently differentiated.
- Management teams and backers will face greater pressure to distinguish durable demand from pandemic-driven utilization rather than relying on the sector's earlier funding momentum.
Third-order effects
- If this divergence persists, digital health financing may concentrate around companies that can show clearer differentiation and public-market resilience, rather than treating the sector as a single growth category.
- The sector's post-pandemic transition suggests capital markets are moving from broad thematic enthusiasm toward company-by-company underwriting of healthcare technology.
The trend: Digital health is shifting from pandemic-era, sector-wide capital abundance to a more selective market that rewards demonstrable durability and differentiation.